Perceptive Advisors is a venture capital firm that primarily invests in early-stage life sciences companies, including those in biotechnology, pharmaceuticals, and health tech sectors. Their strategy involves leading or co-leading Series A financings, with a focus on advancing differentiated technologies from preclinical stages through clinical proof-of-concept.
Portfolio
5
Fund Size
$8.5B
Top Stage
Series B
Last 12 Mo
0
Stage Distribution
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Rapport Therapeutics | Series B | $150M | Aug 2023 |
| Freenome | Series D | $300M | Dec 2021 |
| Bridge to Life | Series A | $56M | Aug 2021 |
| Prometheus Biosciences | Growth | $130M | Nov 2020 |
| Kindbody | Series B | $32M | — |
Top Co-Investors
Cormorant Asset Management3 shared
GV (Google Ventures)2 shared
T. Rowe Price Associates, Inc.2 shared
RRE Ventures1 shared
TQ Ventures1 shared
Trail Mix Ventures1 shared
Winklevoss Capital1 shared
Sofinnova Partners1 shared
Goldman Sachs1 shared
ARCH Venture Partners1 shared
RA Capital Management1 shared
Bain Capital Life Sciences1 shared
Catalio Capital Management1 shared
DCVC1 shared
Janus Henderson Investors1 shared
Kaiser Permanente Ventures1 shared
Novartis Venture Fund1 shared
Polaris Venture Partners1 shared
Sands Capital1 shared
Last updated: 27 February 2026